Latest Regulatory Milestones News

Euro Manganese has cleared major regulatory hurdles for its Chvaletice Manganese Project, securing construction and land planning permits that significantly reduce project risk and pave the way for production in Europe’s only near-term high-purity manganese source.

Australian Silica Quartz Group (ASQ) has cleared a key regulatory hurdle with DMPE approval for the White Swan Kaolin Project’s Mining Development and Closure Proposal, paving the way for bulk sampling and offtake talks ahead of mining.

Aguia Resources has received official commercialisation approval for its Pampafos phosphate fertiliser project, enabling invoicing and marketing ahead of a targeted sales campaign designed to boost cash flow by mid-2026.

Bio-Gene Technology has raised A$3.21 million to complete critical safety studies for its novel insecticide Flavocide and ramp up production of its natural insecticide Qcide, advancing its path to commercialisation in multiple global markets.

Osteopore has secured Hainan FDA approval to clinically use and sell its custom orthopaedic devices at Shanghai Ruijin Hospital’s Hainan branch, marking a key step towards wider China market access. The company has scheduled its first patient surgery for June 2026.

Anteris Technologies Global Corp. has initiated an at-the-market equity offering to raise up to US$250 million, aiming to accelerate development of its DurAVR transcatheter heart valve and support general corporate needs.

Aurum Resources has cleared a major regulatory hurdle with three environmental certificates granted for its 3.22Moz Boundiali Gold Project in Côte d’Ivoire, bringing the project closer to mining licence approval.

1414 Degrees Limited has responded to an ASX price query after its shares jumped from $0.056 to $0.097 in days, confirming no undisclosed information but highlighting progress in aerospace and energy projects.

Argenica Therapeutics has passed a critical FDA genotoxicity test for its stroke drug ARG-007, advancing its IND application and edging closer to Phase 2b clinical trials in the US and Australia.

Terrain Minerals is progressing steadily towards a maiden Mineral Resource Estimate (MRE) for its Lightning Gold Project, targeting July 2026. Key technical and regulatory milestones are being ticked off, underpinning the project’s transition from exploration to resource definition.

BLIS Technologies posted a 16% revenue increase to $14.7 million in FY26, resolving a key intellectual property dispute and expanding strategic partnerships, including an extended Probi AB agreement that now covers pet nutrition.

Patrys has appointed CMAX and Alithia Life Sciences to lead its Phase 1A clinical trial operations for RLS-2202, advancing its injectable quetiapine program toward first-in-human testing in Q3 2026, pending ethics approval.